The PE Ratio as of November 2024 (TTM) for Xencor, Inc. (XNCR) is -7.47

According to Xencor, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.47. This represents a change of -23.12% compared to the average of -9.72 of the last 4 quarters.

Xencor, Inc. (XNCR) Historical PE Ratio (quarterly & annually)

How has XNCR PE Ratio performed in the past?

The mean historical PE Ratio of Xencor, Inc. over the last ten years is -4.26. The current -7.47 PE Ratio has changed 17.42% with respect to the historical average. Over the past ten years (40 quarters), XNCR's PE Ratio was at its highest in in the September 2018 quarter at 171.34. The PE Ratio was at its lowest in in the March 2021 quarter at -251.04.

Xencor, Inc. (XNCR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Xencor, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xencor, Inc. (XNCR) Average PE Ratio

How has XNCR PE Ratio performed in the past?

The current PE Ratio of Xencor, Inc. (XNCR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xencor, Inc. (XNCR) PE Ratio vs. Peers

How is XNCR’s PE Ratio compared to its peers?

Xencor, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-27.83), greater than Keros Therapeutics, Inc. (-12.88), less than Monte Rosa Therapeutics, Inc. (-4.83), less than Mineralys Therapeutics, Inc. (-5.57), less than Erasca, Inc. (-3.95), greater than Kura Oncology, Inc. (-8.49), less than Protagonist Therapeutics, Inc. (16.87), greater than Merus N.V. (-14.30), less than Replimune Group, Inc. (-3.78), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than IDEAYA Biosciences, Inc. (-14516.37), less than AnaptysBio, Inc. (-3.21), less than MeiraGTx Holdings plc (-4.12), less than Homology Medicines, Inc. (-0.01), greater than Nuvalent, Inc. (-33.32), greater than DICE Therapeutics, Inc. (-23.17), greater than Arcellx, Inc. (-85.84), greater than Vaxcyte, Inc. (-25.11), less than Viridian Therapeutics, Inc. (-6.40), less than Larimar Therapeutics, Inc. (-7.46), less than Syndax Pharmaceuticals, Inc. (-6.12), less than Sutro Biopharma, Inc. (-2.41),

Build a custom stock screener for Xencor, Inc. (XNCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xencor, Inc. (XNCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.